<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377608</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000171</org_study_id>
    <nct_id>NCT03377608</nct_id>
  </id_info>
  <brief_title>Modifiers of Tenofovir in the Female Genital Tract</brief_title>
  <official_title>Modifiers of Tenofovir Exposure in the Female Genital Tract of African Women on Depo-provera</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MU-JHU CARE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two-armed, single visit, pharmacokinetic study to compare tenofovir diphosphate&#xD;
      concentrations in cervical tissues of women on Depo-Provera contraception vs non-hormonal&#xD;
      contraception.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Actual">April 2, 2018</completion_date>
  <primary_completion_date type="Actual">March 29, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cervical Tissue Concentrations</measure>
    <time_frame>Day 1</time_frame>
    <description>Assess the influence of hormonal contraception on tenofovir concentrations in cervical tissues</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proinflammatory cytokines</measure>
    <time_frame>Day 1</time_frame>
    <description>To determine relationship between local inflammation and drug disposition in the female genital tract</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression of drug metabolizing enzymes and transporters</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the influence of hormonal contraception on the expression of drug metabolizing enzymes and transporters in cervical tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal microbiome</measure>
    <time_frame>Day 1</time_frame>
    <description>To identify potential role of the vaginal microbiome in local drug disposition</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Depo-Provera</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-hormonal contraception</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit</description>
    <arm_group_label>Depo-Provera</arm_group_label>
    <arm_group_label>Non-hormonal contraception</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depo-Provera</intervention_name>
    <description>Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit</description>
    <arm_group_label>Depo-Provera</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women will be recruited from an existing cohort.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, or transgender female with a cervix, aged 18-35 years old&#xD;
&#xD;
          -  HIV-positive&#xD;
&#xD;
          -  Stable on antiretroviral regimen containing TDF for at least 2 weeks at time of&#xD;
             enrollment.&#xD;
&#xD;
          -  Virally suppressed (HIV-RNA copies &lt;50 copies/mL) for at least 6 months at time of&#xD;
             enrollment.&#xD;
&#xD;
          -  Willing to refrain from vaginal intercourse and use of vaginal devices such as douches&#xD;
             and sex toys within 72 hours of the biopsy visit.&#xD;
&#xD;
          -  Willing and able to give signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently pregnant or previous pregnancy within 3 months of enrollment&#xD;
&#xD;
          -  Currently breast feeding&#xD;
&#xD;
          -  Symptomatic vaginal infection within 2 weeks prior to enrollment&#xD;
&#xD;
          -  Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or&#xD;
             following vaginal intercourse, or gynecologic surgery within 90 days prior to&#xD;
             enrollment&#xD;
&#xD;
          -  History of vulvar/vaginal/ cervical dysplasia, neoplasia or cancer, atypical squamous&#xD;
             cells of undetermined significance, condyloma, or human papilloma virus (HPV) in the&#xD;
             past year&#xD;
&#xD;
          -  Use of oral and/or vaginal preparations of antibiotic or antifungal medications within&#xD;
             30 days prior to the enrollment visit&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MU-JHU Care Ltd</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>December 8, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tenofovir</keyword>
  <keyword>microbiome</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

